FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081344691> ?p ?o ?g. }

• W3081344691 endingPage "368" @default.
• W3081344691 startingPage "355" @default.
• W3081344691 abstract "Drug-eluting beads transarterial chemoem-bolization (DEB-TACE) has the advantages of slow and steady release, high local concentration, and low incidence of adverse drug reactions compared to the traditional TACE. DEB-TACE combined with sequentially ultrasound-guided radiofrequency ablation (RFA) therapy has strong anti-cancer effects and little side effects, but there are fewer related long-term studies until now.To explore the outcome of DEB-TACE sequentially combined with RFA for patients with primary hepatocellular carcinoma (HCC).Seventy-six patients with primary HCC who underwent DEB-TACE sequentially combined with RFA were recruited. Forty patients with untreated HCC were included in Group A, and 36 patients with recurrent HCC were included in Group B. In addition, 40 patients with untreated HCC who were treated with hepatectomy were included in Group C. The serological examination, preoperative magnetic resonance imaging examination, and post-treatment computed tomography enhanced examination were performed for all patients. The efficacy was graded as complete remission (CR), partial remission (PR), stable disease and progressive disease at the 3rd, 6th, and 9th. All patients were followed up for 3 years and their overall survival (OS), disease-free survival (DFS) were assessed.The efficacy of Group A and Group C was similar (P > 0.05), but the alanine aminotransferase, aspartate aminotransferase and total bilirubin of Group A were lower than those of Group C (all P < 0.05). The proportions of CR (32.5%), PR (37.5%) were slightly higher than Group A (CR: 27.5%, PR: 35%), but the difference was not statistically significant (χ2 = 0.701, P = 0.873). No operational-related deaths occurred in Group A and Group C. The OS (97.5%, 84.7%, and 66.1%) and the DFS (75.0%, 51.7%, and 35.4%) of Group A at the 1st, 2nd, and 3rd year after treatment were similar with those of Group C (OS: 90.0%, 79.7%, and 63.8%; DFS: 80.0%, 59.7%, and 48.6%; P > 0.05). The OS rates in Group A and Group B (90%, 82.3%, and 66.4%) were similar (P > 0.05). The DFS rates in Group B (50%, 31.6%, and 17.2%) were lower than that of Group A (P = 0.013).The efficacy of DEA-TACE combined with RFA for untreated HCC is similar with hepatectomy. Patients with recurrent HCC could get a longer survival time through the combined treatment." @default.
• W3081344691 created "2020-09-01" @default.
• W3081344691 creator A5001562019 @default.
• W3081344691 creator A5026412012 @default.
• W3081344691 creator A5030847742 @default.
• W3081344691 creator A5038994386 @default.
• W3081344691 creator A5046833692 @default.
• W3081344691 creator A5059849089 @default.
• W3081344691 creator A5075454825 @default.
• W3081344691 date "2020-08-27" @default.
• W3081344691 modified "2023-09-26" @default.
• W3081344691 title "Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma" @default.
• W3081344691 cites W1884276124 @default.
• W3081344691 cites W1934479321 @default.
• W3081344691 cites W1984180316 @default.
• W3081344691 cites W2013670632 @default.
• W3081344691 cites W2030982182 @default.
• W3081344691 cites W2045775115 @default.
• W3081344691 cites W2074796328 @default.
• W3081344691 cites W2079586464 @default.
• W3081344691 cites W2121690051 @default.
• W3081344691 cites W2142478451 @default.
• W3081344691 cites W2165573336 @default.
• W3081344691 cites W2168526573 @default.
• W3081344691 cites W2172053487 @default.
• W3081344691 cites W2271655714 @default.
• W3081344691 cites W2277004004 @default.
• W3081344691 cites W2296490141 @default.
• W3081344691 cites W2296767826 @default.
• W3081344691 cites W2323299577 @default.
• W3081344691 cites W2398912501 @default.
• W3081344691 cites W2461796595 @default.
• W3081344691 cites W2554821140 @default.
• W3081344691 cites W2563666726 @default.
• W3081344691 cites W2582878252 @default.
• W3081344691 cites W2594376758 @default.
• W3081344691 cites W2595685820 @default.
• W3081344691 cites W2598240561 @default.
• W3081344691 cites W2665614638 @default.
• W3081344691 cites W2729904693 @default.
• W3081344691 cites W2765496667 @default.
• W3081344691 cites W2773983000 @default.
• W3081344691 cites W2783948736 @default.
• W3081344691 cites W2803786348 @default.
• W3081344691 cites W2827438165 @default.
• W3081344691 cites W2915581298 @default.
• W3081344691 cites W2917844237 @default.
• W3081344691 cites W2922394035 @default.
• W3081344691 cites W2955801272 @default.
• W3081344691 cites W2963893422 @default.
• W3081344691 cites W2970994473 @default.
• W3081344691 cites W2973365430 @default.
• W3081344691 cites W2979389959 @default.
• W3081344691 cites W2987490208 @default.
• W3081344691 cites W2989639179 @default.
• W3081344691 cites W2991156366 @default.
• W3081344691 cites W2998347858 @default.
• W3081344691 cites W3148676889 @default.
• W3081344691 cites W4246778826 @default.
• W3081344691 cites W785055818 @default.
• W3081344691 doi "https://doi.org/10.4240/wjgs.v12.i8.355" @default.
• W3081344691 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7448208" @default.
• W3081344691 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32903981" @default.
• W3081344691 hasPublicationYear "2020" @default.
• W3081344691 type Work @default.
• W3081344691 sameAs 3081344691 @default.
• W3081344691 citedByCount "6" @default.
• W3081344691 countsByYear W30813446912021 @default.
• W3081344691 countsByYear W30813446912022 @default.
• W3081344691 countsByYear W30813446912023 @default.
• W3081344691 crossrefType "journal-article" @default.
• W3081344691 hasAuthorship W3081344691A5001562019 @default.
• W3081344691 hasAuthorship W3081344691A5026412012 @default.
• W3081344691 hasAuthorship W3081344691A5030847742 @default.
• W3081344691 hasAuthorship W3081344691A5038994386 @default.
• W3081344691 hasAuthorship W3081344691A5046833692 @default.
• W3081344691 hasAuthorship W3081344691A5059849089 @default.
• W3081344691 hasAuthorship W3081344691A5075454825 @default.
• W3081344691 hasBestOaLocation W30813446911 @default.
• W3081344691 hasConcept C120665830 @default.
• W3081344691 hasConcept C121332964 @default.
• W3081344691 hasConcept C126322002 @default.
• W3081344691 hasConcept C126838900 @default.
• W3081344691 hasConcept C141071460 @default.
• W3081344691 hasConcept C143409427 @default.
• W3081344691 hasConcept C197934379 @default.
• W3081344691 hasConcept C2776231280 @default.
• W3081344691 hasConcept C2776694085 @default.
• W3081344691 hasConcept C2777377203 @default.
• W3081344691 hasConcept C2777785397 @default.
• W3081344691 hasConcept C2778019345 @default.
• W3081344691 hasConcept C2778822529 @default.
• W3081344691 hasConcept C2778902805 @default.
• W3081344691 hasConcept C61511704 @default.
• W3081344691 hasConcept C71924100 @default.
• W3081344691 hasConcept C90924648 @default.
• W3081344691 hasConceptScore W3081344691C120665830 @default.
• W3081344691 hasConceptScore W3081344691C121332964 @default.

• next